Veradigm Files Long-Delayed 10-Ks, Reveals $292M 2024 Loss
Event summary
- Veradigm filed its 2023 and 2024 Form 10-Ks on May 26, 2026, resolving a significant regulatory backlog.
- 2024 revenue declined to $594M from $626M in 2023, with a net loss of $292M compared to a $49M profit in 2023.
- Adjusted EBITDA dropped to $94M in 2024 from $132M in 2023.
- CEO Donald Trigg cited progress in Q1 2026 and expects 2026 revenue to benefit from a focused product strategy.
- The company aims to file its 2025 Form 10-K by year-end 2026 and relist its stock on a national exchange.
The big picture
Veradigm's filing of its long-overdue 10-Ks marks a critical step in regaining regulatory compliance and investor confidence. The company's significant 2024 loss and revenue decline highlight the challenges in the healthcare IT sector, particularly for providers of clinical and revenue cycle solutions. The strategic shift towards AI investments and cost management reflects broader industry trends towards digital transformation and operational efficiency. The success of these initiatives will be key to Veradigm's ability to reclaim its market position and achieve sustainable growth.
What we're watching
- Financial Recovery
- Whether Veradigm's AI-specific investments and cost actions can sustain profitability improvements.
- Regulatory Compliance
- The pace at which Veradigm can complete its 2025 and 2026 filings and relist its stock.
- Market Positioning
- How Veradigm's refocused product strategy will impact its leadership in independent practice solutions.
Related topics